Source:http://linkedlifedata.com/resource/pubmed/id/11073751
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2000-12-26
|
| pubmed:abstractText |
Forty-one cases of toxoplasmosis were diagnosed in 15 European transplantation centers in patients who had undergone allogeneic hematopoietic stem cell transplantation (HSCT) from 1994 through 1998. Most patients (39 [94%]) were seropositive for Toxoplasma gondii before they underwent transplantation, and 30 (73%) had developed moderate to severe acute graft-versus-host disease before they developed toxoplasmosis. Thirty-five (85%) patients had Toxoplasma disease with evidence of organ involvement, whereas 6 (15%) patients had Toxoplasma infection, as defined by fever and a positive polymerase chain reaction (PCR) finding for T. gondii in blood. Nine patients were diagnosed at autopsy. Thirty patients (73%) had not received antimicrobial prophylaxis with anti-Toxoplasma activity after undergoing transplantation. The median day of onset of disease after HSCT was 64. Twenty-two (63%) patients died from toxoplasmosis, and 23 (66%) received adequate anti-Toxoplasma therapy for > or =3 days. Among these 23 patients, 11 (48%) showed a complete response and 3 (13%) showed improvement. In univariate and multivariate analyses, having received adequate therapy and experiencing late infection (>63 days after HSCT) were associated with a lower risk of dying from toxoplasmosis. Toxoplasmosis after HSCT is a severe infection with a high mortality rate even when diagnosed soon after HSCT, and PCR may help establish the diagnosis earlier.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiprotozoal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Clindamycin,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimethamine,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfadiazine,
http://linkedlifedata.com/resource/pubmed/chemical/Trimethoprim-Sulfamethoxazole...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1058-4838
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1188-95
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11073751-Adolescent,
pubmed-meshheading:11073751-Adult,
pubmed-meshheading:11073751-Animals,
pubmed-meshheading:11073751-Antiprotozoal Agents,
pubmed-meshheading:11073751-Autopsy,
pubmed-meshheading:11073751-Child,
pubmed-meshheading:11073751-Clindamycin,
pubmed-meshheading:11073751-Drug Therapy, Combination,
pubmed-meshheading:11073751-Female,
pubmed-meshheading:11073751-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11073751-Humans,
pubmed-meshheading:11073751-Male,
pubmed-meshheading:11073751-Middle Aged,
pubmed-meshheading:11073751-Pyrimethamine,
pubmed-meshheading:11073751-Sulfadiazine,
pubmed-meshheading:11073751-Survival Rate,
pubmed-meshheading:11073751-Toxoplasma,
pubmed-meshheading:11073751-Toxoplasmosis,
pubmed-meshheading:11073751-Trimethoprim-Sulfamethoxazole Combination
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Toxoplasmosis after hematopoietic stem cell transplantation.
|
| pubmed:affiliation |
Servei d'Hematologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. rmartino@hsp.santpau.es
|
| pubmed:publicationType |
Journal Article,
Multicenter Study
|